CaMKII gene therapy (Mount Sinai Medical Center)

N/A

Report date: 2025/02/25 11:27:45

Base Information

Drug NameCaMKII gene therapy (Mount Sinai Medical Center)
Drug Alias NameAAV-based gene therapy (Mount Sinai Medical Center)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionCalcium/calmodulin-dependent protein kinase type II subunit delta stimulants
TargetsCalcium/calmodulin-dependent protein kinase type II subunit delta
Therapy Area/IndicationsBlindness
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMount Sinai Medical Center/Miami Jewish Home Andhospital For Theed Home Healthency
China Registration ClassN/A

Develop Information

Active CompaniesMount Sinai Medical Center/Miami Jewish Home Andhospital For Theed Home HealthencyYale School Of MedicineMichigan State University
Inactive CompaniesN/A
Active IndicationsBlindness
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A